Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 7/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 3/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8190674 | 0.81 | KCNH2 (0.41) | KCNH2TMEM97SIGMAR1CSNK2A1CYP4F2 | |
| SCHEMBL8180613 | 0.81 | CSNK2A1 (0.41) | KCNH2TMEM97SIGMAR1CSNK2A1CYP4F2 | |
| SCHEMBL13547874 | 0.81 | CA2 (0.42) | CYP4F2CYP4A11ESR1 | |
| SCHEMBL12866848 | 0.80 | KCNH2 (0.47) | KCNH2TMEM97SIGMAR1CSNK2A1ESR1 | |
| SCHEMBL13547943 | 0.80 | CSNK2A1 (0.49) | KCNH2TMEM97SIGMAR1CSNK2A1ESR1 | |
| SCHEMBL12867251 | 0.80 | KCNH2 (0.35) | KCNH2TMEM97SIGMAR1CSNK2A1RXRA | |
| SCHEMBL8199280 | 0.79 | GABRA1 (0.41) | KCNH2TMEM97SIGMAR1CSNK2A1CYP4F2 | |
| SCHEMBL13547891 | 0.78 | KCNH2 (0.43) | KCNH2TMEM97SIGMAR1CYP4F2CYP4A11 | |
| SCHEMBL12866948 | 0.78 | KCNH2 (0.38) | KCNH2TMEM97SIGMAR1ESR1RXRA | |
| SCHEMBL13181760 | 0.75 | CSNK2A1 (0.37) | KCNH2TMEM97SIGMAR1CSNK2A1CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | PFIZER, INC. | 2011-02-24 | — | — | US | disclosed |
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | PFIZER, INC. | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | SNCA, PARK7, HTT | KCNH2 726/4885TMEM97 1020/4885SIGMAR1 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.